Seroprevalence of Helicobacter pylori in patients with symptoms of upper gastro intestinal tract at a tertiary care hospital

2016-10-21T00-09-15Z
Source: International Journal of Research in Medical Sciences
Ramakumar Manimaran, Ananthi Boj.
Background: The association of helicobacter pylori with upper gastrointestinal diseases is widely reported. Currently according to guidelines the test and treat option is preferable in population with a moderate to high prevalence of Helicobacter pylori infection (≥10%), and empiric trial of acid suppression with a proton pump inhibitor for 4 to 8 weeks in low prevalence situation. Hence prevalence rate of Helicobacter pylori is significant for the treatment strategies. Aim of the study was to determine the prevalence of Helicobacter pylori in patients with symptoms of upper gastrointestinal tract in our tertiary care hospital and to analyse its distribution according to age and sex. Methods: The study was conducted in the department of surgery at ACS medical college for a period of 6 months from February 2016 to July 2016.Adult patients attending the outpatient department in our hospital with symptoms of upper gastrointestinal tract for more than 6 weeks were evaluated for Helicobacter pylori by doing the immuno-card test one step antibodies to Helicobacter pylori (SD Bioloine). Analysis of Helicobacter pylori distribution according to age and sex were done in these positive patients. Results: Out of 400 patients, 117 were found positive for Helicobacter pylori by giving a prevalence rate of 29.25%. Age-wise distribution showed prevalence rate progressively increased with age and the high prevalence was seen in the 41 to 50 years age group and thereafter decreased gradually in the older age groups. High prevalence was observed in males, as out of the 117 Helicobacter pylori positive patients, 74 (63.25%) were males and 43 (36.75%) were females. Conclusions: The prevalence of Helicobacter pylori infection in patients with symptoms of upper gastrointestinal tract was lower than rates reported in developing countries. But as the prevalence rates in our study is more than 10%, the test and treat approach is more appropriate than starting empirical treatment with a proton pump inhibitor.


http://ift.tt/2eXDvfh